Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kyverna Therapeutics (KYTX) Free Cash Flow (2023 - 2026)

Kyverna Therapeutics posted quarterly Free Cash Flow of -$41.6 million for Q1 2026, up 7.35% year-on-year from -$38.8 million in Q1 2025, and down 24.11% on a QoQ basis from -$33.5 million in Q4 2025.

Kyverna Therapeutics (KYTX) has 4 years of Free Cash Flow data on file, last reported at -$41.6 million in Q1 2026.

  • For the quarter ending Q1 2026, Free Cash Flow rose 7.35% year-over-year to -$41.6 million; the trailing twelve-month figure through Mar 2026 stood at -$150.4 million (down 11.13% YoY), and the FY2025 full-year result was -$153.7 million, down 31.93% from the prior year.
  • Free Cash Flow for Q1 2026 stood at -$41.6 million, down from -$33.5 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$11.3 million in Q2 2023 and bottomed at -$44.9 million in Q1 2025.
  • The 4-year median for Free Cash Flow is -$29.2 million (2024), against an average of -$28.1 million.
  • The widest annual swing landed in 2024, when Free Cash Flow sank 155.9%; it then gained 10.95% in 2025.
  • A 4-year view of Free Cash Flow shows it stood at -$18.9 million in 2023, then tumbled by 99.31% to -$37.6 million in 2024, then rose by 10.95% to -$33.5 million in 2025, then slipped by 24.11% to -$41.6 million in 2026.
  • The last three Free Cash Flow figures came in at -$41.6 million (Q1 2026), -$33.5 million (Q4 2025), and -$43.3 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Free Cash Flow (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -1.67 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -12.20 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -2.49 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 1.29 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 848.30 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 48.67 Mn
10 Kyverna Therapeutics 497.98 Mn 265.03 Mn - -41.60 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -41.60 Mn
Mar 31, 2026 -41.60 Mn
Dec 31, 2025 -33.52 Mn
Dec 31, 2025 -33.52 Mn
Sep 30, 2025 -43.32 Mn
Sep 30, 2025 -43.32 Mn
Jun 30, 2025 -31.97 Mn
Jun 30, 2025 -31.97 Mn
Mar 31, 2025 -44.90 Mn
Mar 31, 2025 -44.90 Mn
Dec 31, 2024 -37.64 Mn
Dec 31, 2024 -37.64 Mn
Sep 30, 2024 -29.16 Mn
Sep 30, 2024 -29.16 Mn
Jun 30, 2024 -23.63 Mn
Jun 30, 2024 -23.63 Mn
Mar 31, 2024 -26.07 Mn
Mar 31, 2024 -26.07 Mn
Dec 31, 2023 -18.89 Mn
Dec 31, 2023 -18.89 Mn
Sep 30, 2023 -11.40 Mn
Sep 30, 2023 -11.40 Mn
Jun 30, 2023 -11.25 Mn
Jun 30, 2023 -11.25 Mn
Mar 31, 2023 -11.49 Mn
Mar 31, 2023 -11.49 Mn